Business Wire

CA-LEGENDARY-PICTURES

25.8.2022 16:02:11 CEST | Business Wire | Press release

Share
Director Adam Wingard Returns as Warner Bros. Pictures and Legendary Pictures Explore the Next Chapter in the Massive Monsterverse Franchise

Coming off the global success of 2021’s “Godzilla vs Kong” cameras are now rolling on the latest entry in Warner Bros. Pictures’ and Legendary Pictures’ cinematic Monsterverse. This latest entry follows up the explosive showdown of Godzilla vs. Kong with an all-new cinematic adventure, pitting the almighty Kong and the fearsome Godzilla against a colossal undiscovered threat hidden within our world, challenging their very existence – and our own. The epic new film will delve further into the histories of these Titans, their origins and the mysteries of Skull Island and beyond, while uncovering the mythic battle that helped forge these extraordinary beings and tied them to humankind forever.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005274/en/

The film, which recently began principal photography, is again being helmed by director Adam Wingard (“You’re Next” “The Guest”) and stars returning cast members Rebecca Hall (“The Night House” “Resurrection”), Brian Tyree Henry (“Bullet Train” “Atlanta”), and Kaylee Hottle (“Godzilla vs. Kong”), who are now joined by newcomers Dan Stevens (“Gaslit” “Legion” “Beauty and the Beast”), Fala Chen (“Irma Vep” “Shang Chi and the Legend of the Ten Rings”), Alex Ferns (“The Batman” “Wrath of Man” “Chernobyl”) and Rachel House (“Hunt for the Wilderpeople” “Thor: Ragnarok” “Foundation”).

Wingard is directing the currently untitled project from a script by Terry Rossio (“Godzilla vs. Kong” the “Pirates of the Caribbean” series), Jeremy Slater (“Moon Knight”) and Simon Barrett (“You’re Next”). The film is being produced by Mary Parent, Alex Garcia, Eric Mcleod, Brian Rogers, Thomas Tull, and Jon Jashni, with executive producers Josh Grode, Adam Wingard, Jay Ashenfelter, Jen Conroy, Kenji Okuhira and Yoshimitsu Banno.

Once again, Wingard is collaborating with director of photography Ben Seresin (“Godzilla vs. Kong” “World War Z”), production designer Tom Hammock (“Godzilla vs. Kong” “X” “The Guest”), editor Josh Schaeffer (“Godzilla vs. Kong” “Molly’s Game”), and composer Tom Holkenborg (“Godzilla vs. Kong” “Mad Max: Fury Road”), who are now joined by costume designer Emily Seresin (“The Invisible Man” “Top of the Lake”), makeup artist Sabrina Wilson (“Captain Marvel” “The Suicide Squad” “The Book of Bobba Fett”), hairstylist Gloria Pasqua Casny (“The Tomorrow War” “Ford vs Ferrari”), and VFX supervisor Alessandro Ongaro (“The Adam Project” “Ghostbusters: Afterlife”).

The film is being shot on location in Queensland, Australia and is slated for a March 15, 2024, worldwide release from Warner Bros. Pictures except in Japan where it will be distributed by Toho Co., Ltd and in mainland China where it will be distributed by Legendary East.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye